Fusion protein · Immune activation, directed at IL-2 receptor beta subunit (CD122) (IL2RB) and IL-2 receptor gamma subunit (CD132) (IL2RG) · developed by Xilio Development
XTX202 is a protease-masked form of recombinant interleukin-2 that stays inactive until cleaved by proteases in the tumor microenvironment. Once released, IL-2 binds the CD122 and CD132 subunits on CD8+ T effector cells and natural killer cells, activating them against tumor cells. It is studied in advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05052268 | Phase 1/2 | Advanced Solid Tumor | Completed | XLO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid Tumor
See XLO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
XLO catalysts and pipeline →